MATK Insider Trading Activity and SEC Form 4 Filings
MATK insider trading summary
No open-market insider purchases or sales of Martek Biosciences Corp (MATK) have been reported on SEC Form 4 in the past 12 months.
Latest MATK insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Feb 24, 2011 | Royal DSM N.V. | 10% Owner | Buy | $7.7M (245,302 @ $31.50) |
| Feb 23, 2011 | Royal DSM N.V. | 10% Owner | Buy | $536K (17,000 @ $31.50) |
| Feb 22, 2011 | Royal DSM N.V. | 10% Owner | Buy | $1K (32 @ $31.50) |
| Feb 22, 2011 | Royal DSM N.V. | 10% Owner | Buy | $495.0M (15,712,946 @ $31.50) |
| Jul 7, 2010 | Steve Dubin | Chief Executive Officer | Buy | $42K (2,000 @ $20.96) |
| Sep 23, 2009 | Douglas J Macmaster Jr | Director | Sell | $117K (4,907 @ $23.80) |
| Jun 18, 2008 | Douglas J Macmaster Jr | Director | Sell | $269K (8,000 @ $33.61) |
| Jun 18, 2008 | Harry J D'Andrea | Director | Sell | $51K (1,500 @ $34.03) |
| Dec 21, 2007 | James Beery | Director | Sell | $3K (88 @ $28.73) |
| Dec 21, 2007 | James Beery | Director | Sell | $12K (412 @ $28.74) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.